ESR1 and neoplasm: Having certain mutations might carry a potential for more favorable response, as suggested by a subgroup analysis revealing that patients with PIK3CA and ESR1 mutations detected by liquid biopsy when analyzing circulating tumor DNA (ctDNA) had more favorable responses (33), making the argument to keep looking for predictive biomarkers even more powerful.